Dr. Mehmet Akce, MD

Dr. Akce practices at University of Alabama Birmingham Hospital in Birmingham, Alabama.

Dr. Akce's NPI, 1639480106, was assigned on June 29, 2010. Dr. Akce holds Alabama license 44443.

Dr. Akce's primary practice is University of Alabama Birmingham Hospital, at 619 19th S St, Birmingham, AL 35211 in Jefferson County. The practice phone is (205) 731-9770.

Dr. Akce's primary practice is University of Alabama Birmingham Hospital in Birmingham, Alabama. Dr. Akce is also affiliated with UAB Hospital. The medical group on file is UAB Medicine.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Akce practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Akce's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Akce's licenses on file in 3 states: Alabama, Georgia and Michigan.

CMS data shows 368 Medicare services from Dr. Akce across 4 procedure codes in 2024, for 97 Medicare patients. Medicare paid $22,186 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 97 Medicare patients who saw Dr. Akce in 2024. The largest group is 65 to 74, with 51 patients. 75% of them have high blood pressure, and 56% have high cholesterol. 15% are also on Medicaid. Their average risk score is 2.54, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Akce's median patient age at 65, with 39% women.

In 2024, Dr. Akce wrote 536 Medicare Part D claims for 93 patients. 83% of them were for generic drugs. CMS names the drug for 344 of them, across 13 drugs with 11 or more claims each, at $219,823 in total drug cost. In 2023, CMS named 343 claims across 14 drugs.

Dr. Akce accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Akce as offering telehealth.

Dmand AI links 58 papers to Dr. Akce, published from 2012 to 2025. 2019 was the busiest year, with 9. The most frequent topics are Liver Neoplasms, Carcinoma, Hepatocellular and Pancreatic Neoplasms. Dr. Akce has published most often in Chin Clin Oncol. Dr. Akce's most frequent co-authors are Bassel Fouad El-Rayes, MD, Olatunji B. Alese, MD and Christina Sing-Ying Wu, MD.

Dmand AI links Dr. Akce to 10 clinical trials, 6 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Rectal Diseases, Colorectal Neoplasms and Carcinoma, Hepatocellular. Academic and Community Cancer Research United sponsors the most, 2.

CMS Open Payments shows 250 general payments to Dr. Akce from 34 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 81% of the total. AstraZeneca Pharmaceuticals LP paid the most, $18,675.